DCTs Can Work, But Expect More Time & Costs

Dr. Oscar Segurado, the chief medical officer of gene therapy company, ASC Therapeutics, has seen the advantages of a DCT firsthand with his company’s Phase 1 trial, and he talks about the changes he’s had to adapt to when it comes to running these trials.

View the full presentation here.